Table 3 Multivariate analysis of transplant outcomes in intermediate-risk AML adults with FLT3-ITD transplanted in CR1 MRD negative.

From: Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT

 

RI

NRM

LFS

OS

 

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HAPLO vs ASCT

0.14 (0.07–0.28)

<0.0001

3.43 (1.55–7.61)

0.002

0.53 (0.34–0.85)

0.007

0.83 (0.52–1.33)

0.44

Age (per 10 years)

0.86 (0.71–1.05)

0.14

1.54 (1.17–2.02)

0.002

1.09 (0.94–1.27)

0.27

1.19 (1–1.4)

0.048

Year of HSCT

0.95 (0.88–1.03)

0.25

0.87 (0.78–0.97)

0.013

0.93 (0.87–1)

0.04

0.9 (0.84–0.97)

0.004

Female vs male

1.21 (0.73–2)

0.45

1.54 (0.86–2.78)

0.15

1.34 (0.92–1.96)

0.13

1.55 (1.02–2.37)

0.042

Time diagnosis to HSCT (mo)

0.98 (0.88–1.1)

0.76

0.94 (0.81–1.08)

0.36

0.96 (0.88–1.05)

0.38

0.96 (0.88–1.05)

0.37

NPM1 mut vs wt

0.46 (0.26–0.8)

0.006

0.6 (0.33–1.1)

0.1

0.5 (0.33–0.76)

0.001

0.56 (0.36–0.87)

0.009

China vs other countries

1.18 (0.32–4.36)

0.81

0.7 (0.23–2.15)

0.54

0.78 (0.31–1.97)

0.6

0.63 (0.27–1.47)

0.29

  1. HR hazard ratio, CI confidential interval, HAPLO haploidentical stem cell transplantation, ASCT autologous stem cell transplantation, HSCT hematopoietic stem cell transplantation, mo months, mut mutation, wt wild-type.
Back to article page